MarketInOut Stock Screener Log In | Sign Up
 

Entera Bio Ltd

NASDAQ • Healthcare • Biotechnology • Quote as of 10/19/2026 16:00
Entera Bio Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization476.31 mln
Float132 mln
Earnings Date11/05/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

9.75
Transformational upside

Relative Strength

97 / 100
Top performer

Debt / Equity

0.06
Debt-free

ROE

-134
Deeply negative

ROA

-99.40
Deeply negative

Business Description

Entera Bio is an Israel-based company focused on turning injectable hormone and protein treatments into pills that patients can swallow. The company has several drugs in clinical testing, targeting conditions such as osteoporosis, obesity, and rare hormonal disorders. Its most advanced candidate is an oral version of teriparatide, a drug commonly used to treat bone loss, which has already completed a mid-stage clinical trial. Entera also works with partner companies to advance additional treatments through early-stage research and testing.

Key Fundamentals

EPS-0.36
ROE-134
ROIC-942
ROA-99.40
Interest Cover-5.24
EBITDA, mln-17.00
EV / EBITDA-28.81
EV / EBIT-28.76
Revenue, mln0.04
EV / Revenue11,664

Quote Details

Last 2.94
Change 0.26 (9.7%)
Open 2.66
Volume 950,782
Turnover 2,795,299
Average Volume 662,410

Financial Ratios

Leverage Ratio2.68
Current Ratio8.98
Price / Book19.40
Price / Tangible Book19.40
Debt / Equity0.06
Price / Sales2,910

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price9.75
Short Ratio5.80
Short % of Float1.44

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.94% 98 / 100   
1 Month -0.68% 62 / 100   
2 Months 81.48% 99 / 100   
6 Months 119% 99 / 100   
1 Year 21.99% 80 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog